NO136843C - Analogifremgangsm}te til fremstilling av terapeutisk aktive derivater av 5,6-dihydro-pyrrolo (3,4-b) pyrazin - Google Patents

Analogifremgangsm}te til fremstilling av terapeutisk aktive derivater av 5,6-dihydro-pyrrolo (3,4-b) pyrazin

Info

Publication number
NO136843C
NO136843C NO62/73A NO6273A NO136843C NO 136843 C NO136843 C NO 136843C NO 62/73 A NO62/73 A NO 62/73A NO 6273 A NO6273 A NO 6273A NO 136843 C NO136843 C NO 136843C
Authority
NO
Norway
Prior art keywords
pyrrolo
pyrazine
dihydro
preparation
therapeutically active
Prior art date
Application number
NO62/73A
Other languages
English (en)
Norwegian (no)
Other versions
NO136843B (no
Inventor
Claude Cotrel
Claude Jeanmart
Mayer Naous Messer
Original Assignee
Rhone Poulenc Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7200505A external-priority patent/FR2166314A1/fr
Priority claimed from FR7239731A external-priority patent/FR2205318A2/fr
Application filed by Rhone Poulenc Sa filed Critical Rhone Poulenc Sa
Publication of NO136843B publication Critical patent/NO136843B/no
Publication of NO136843C publication Critical patent/NO136843C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO62/73A 1972-01-07 1973-01-05 Analogifremgangsm}te til fremstilling av terapeutisk aktive derivater av 5,6-dihydro-pyrrolo (3,4-b) pyrazin NO136843C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7200505A FR2166314A1 (en) 1972-01-07 1972-01-07 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls
FR7239731A FR2205318A2 (en) 1972-11-09 1972-11-09 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls

Publications (2)

Publication Number Publication Date
NO136843B NO136843B (no) 1977-08-08
NO136843C true NO136843C (no) 1977-11-16

Family

ID=26216824

Family Applications (1)

Application Number Title Priority Date Filing Date
NO62/73A NO136843C (no) 1972-01-07 1973-01-05 Analogifremgangsm}te til fremstilling av terapeutisk aktive derivater av 5,6-dihydro-pyrrolo (3,4-b) pyrazin

Country Status (22)

Country Link
US (1) US3862149A (OSRAM)
JP (3) JPS523952B2 (OSRAM)
AR (1) AR195097A1 (OSRAM)
AT (1) AT323181B (OSRAM)
AU (1) AU466586B2 (OSRAM)
BE (1) BE793730A (OSRAM)
CA (1) CA991183A (OSRAM)
CY (1) CY915A (OSRAM)
DD (1) DD102698A5 (OSRAM)
DE (1) DE2300491C3 (OSRAM)
DK (1) DK139359B (OSRAM)
FI (1) FI54124C (OSRAM)
GB (1) GB1358680A (OSRAM)
HK (1) HK60077A (OSRAM)
HU (1) HU164821B (OSRAM)
IE (1) IE37056B1 (OSRAM)
IL (1) IL41232A (OSRAM)
LU (1) LU66800A1 (OSRAM)
NL (1) NL7217852A (OSRAM)
NO (1) NO136843C (OSRAM)
OA (1) OA04285A (OSRAM)
SE (1) SE398503B (OSRAM)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
FR2322601A1 (fr) * 1975-09-04 1977-04-01 Rhone Poulenc Ind Nouveaux derives de l'isoindoline, leur preparation et les compositions qui les contiennent
ATE39483T1 (de) * 1982-04-02 1989-01-15 Takeda Chemical Industries Ltd Kondensierte pyrrolinon-derivate, und ihre herstellung.
JPS6169773A (ja) * 1984-09-14 1986-04-10 Takeda Chem Ind Ltd イソインドリノン誘導体
JPS6297400U (OSRAM) * 1985-12-09 1987-06-20
FR2607504B1 (fr) * 1986-12-02 1989-01-27 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2671800B1 (fr) 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
US5786357A (en) 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
WO1993010787A1 (en) * 1991-12-02 1993-06-10 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
AU3275993A (en) * 1991-12-02 1993-06-28 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
US6348485B1 (en) 1998-06-09 2002-02-19 Takeda Chemical Industries, Ltd. Method for treating or preventing sleep disorders
US6339086B1 (en) * 1999-05-14 2002-01-15 Swpracor, Inc. Methods of making and using N-desmethylzopiclone
ES2203319B1 (es) * 2002-04-03 2005-03-01 Universidad De Oviedo Nuevos carbonatos opticamente activos como intermedios en la sintesis de (+)-zopiclona.
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CA2957667A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
AU2006265008A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and O-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7476737B2 (en) * 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1984371A1 (en) * 2006-02-03 2008-10-29 Synthon B.V. Zopiclone resolution using l-tartaric acid
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
WO2007109799A2 (en) * 2006-03-23 2007-09-27 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
WO2007124025A2 (en) * 2006-04-20 2007-11-01 Teva Pharmaceutical Industries Ltd. Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone
CN101058581B (zh) * 2006-04-21 2011-06-08 天津天士力集团有限公司 右佐匹克隆中间体6-(5-氯-2-吡啶基)-5,7-二氧代-6,7-二氢-5H-吡咯并[3,4-b]吡嗪的制备方法
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008002629A1 (en) * 2006-06-26 2008-01-03 Teva Pharmaceutical Industries Ltd. Process for the preparation of zopiclone
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US7786304B2 (en) * 2006-11-06 2010-08-31 Centaur Pharmaceutical Pvt. Ltd. Process for the preparation of eszopiclone
EP2032557A2 (en) * 2007-01-31 2009-03-11 Teva Pharmaceutical Industries Ltd. Methods for preparing eszopiclone
US20080305171A1 (en) * 2007-06-07 2008-12-11 Kristin Anne Arnold Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
WO2009002552A1 (en) * 2007-06-25 2008-12-31 Teva Pharmaceutical Industries Ltd. Racemization process of r-zopiclone
EP2020403A1 (en) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Process for the resolution of zopiclone and intermediate compounds
US20090198058A1 (en) * 2007-08-06 2009-08-06 Dhananjay Govind Sathe Process for Preparation of Dextrorotatory Isomer of 6-(5- chloro-pyrid-2-yl)-5-[(4-methyl -1-piperazinyl) carbonyloxy] -7-oxo-6,7-dihydro-5H-pyrrolo [3,4-b] pyrazine (Eszopiclone)
KR20100101051A (ko) * 2007-12-11 2010-09-16 씨아이피엘에이 엘티디. 조피클론 결정성 다형체, 이들의 제조 공정 및 이들의 약제 조성물
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CA2747000C (en) * 2007-12-19 2013-09-03 Sunovion Pharmaceuticals Inc. Maleate, besylate, and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CN100467471C (zh) * 2007-12-19 2009-03-11 齐鲁天和惠世制药有限公司 佐匹克隆的制备方法
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US20110053945A1 (en) * 2007-12-19 2011-03-03 Sepracor Inc. Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine
AU2010208240A1 (en) 2009-01-30 2011-09-22 Sunovion Pharmaceuticals Inc Coated tablets of 6-(5-chloro-2-pyridyl) -5-[ (4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6, 7-dihydro-5H-pyrrol o [3,4-b] pyrazine and methods for measuring effectiveness of coating
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN105399745A (zh) * 2015-12-17 2016-03-16 天津华津制药有限公司 一种吡嗪并羟基吡咯烷酮类化合物的制备方法
WO2017214442A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
CN106220630B (zh) * 2016-07-23 2019-12-10 迪嘉药业集团有限公司 一种n-取代吡咯并[3,4-b]吡嗪-5,7(6h)-二酮的制备方法
WO2019226808A1 (en) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3801512A4 (en) 2018-05-29 2022-01-19 President and Fellows of Harvard College COMPOSITIONS AND METHODS FOR REDUCING TOUCH DYSFUNCTION, ANXIETY AND SOCIAL DISABILITY
WO2020198275A1 (en) 2019-03-25 2020-10-01 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
CN114437027A (zh) * 2021-12-22 2022-05-06 深圳市祥根生物医药有限公司 一种佐匹克隆n-氧化杂质的制备方法

Also Published As

Publication number Publication date
JPS5231358B2 (OSRAM) 1977-08-13
JPS5248688A (en) 1977-04-18
AU5075473A (en) 1974-07-04
US3862149A (en) 1975-01-21
BE793730A (fr) 1973-07-05
NL7217852A (OSRAM) 1973-07-10
JPS5248687A (en) 1977-04-18
DK139359C (OSRAM) 1979-07-09
IL41232A0 (en) 1973-03-30
DE2300491A1 (de) 1973-07-19
NO136843B (no) 1977-08-08
JPS535315B2 (OSRAM) 1978-02-25
JPS523952B2 (OSRAM) 1977-01-31
HK60077A (en) 1977-12-09
DD102698A5 (OSRAM) 1973-12-20
AT323181B (de) 1975-06-25
OA04285A (fr) 1979-12-31
CY915A (en) 1977-12-23
DE2300491B2 (de) 1977-09-08
IE37056L (en) 1973-07-07
CA991183A (fr) 1976-06-15
HU164821B (OSRAM) 1974-04-11
FI54124C (fi) 1978-10-10
FI54124B (fi) 1978-06-30
IE37056B1 (en) 1977-04-27
AR195097A1 (es) 1973-09-10
SE398503B (sv) 1977-12-27
AU466586B2 (en) 1975-10-30
GB1358680A (en) 1974-07-03
JPS4876892A (OSRAM) 1973-10-16
DE2300491C3 (de) 1978-05-18
DK139359B (da) 1979-02-05
IL41232A (en) 1975-12-31
LU66800A1 (OSRAM) 1973-07-18

Similar Documents

Publication Publication Date Title
NO136843C (no) Analogifremgangsm}te til fremstilling av terapeutisk aktive derivater av 5,6-dihydro-pyrrolo (3,4-b) pyrazin
NO140301C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazo(5,1-f)-as-triaziner
SE402592B (sv) Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner
NO137012C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive pyrazolo (1,5-a)-pyrimidiner
NO136094C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive d-1-(4-amino-fenyl)-2-alkylamino-etanol-derivater.
NO138565C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive piperazinyl-propyl-1,2,4-triazolinonderivater
NO138566C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,1,3-benzotiadiazol-derivater
FI801764A7 (fi) Farmakologisesti vaikuttavien imidatso/1,5-a//1,4/ diatsepiinien valmistuksessa käytettäviä välituotteita.
NO137966C (no) Analogifremgangsmaate til fremstilling av antibakterielt virksomme 5-oksopyrido-(2,3-d)-pyrimidinderivater
NO136251C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive pyridazin-derivater.
SE389499B (sv) Analogiforfarande for framstellning av triazolo(4,3-a)(1,4)bensodiazepin-derivat
SE402012B (sv) Analogiforfarande for framstellning av s-triazolo(1,5-a)(1,4)diazepinderivat
SE410604B (sv) Analogiforfarande for framstellning av pyrazolo(3,4-e)(1,4)diazepinforeningar
SE411451B (sv) Analogiforfarande for framstellning av derivat av imidazo(4,5-b)pyridiner
NO139735C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimido(4,5-b)kinolin-4(3h)-on-derivater
NO137728C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrasi-4-oksyd-derivater
NO136574C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive pyrimidinderivater.
NO741752L (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminoderivater av pyrazolopyridin-ketoner.
SE397093B (sv) Forfarande for framstellning av oktahydro-oxazolo(3,2-a)pyrrolo(2,1-c)pyrazinderivat
NO140860C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive triazolo-1,5-benzodiazepiner
SE380804B (sv) Anologiforfarande for framstellning av s-triazolo (1,5-a) (1,4)
SE398122B (sv) Analogiforfarande for framstellning av pyrazino/1,2-a/indol-2-karboxamidiner
NO138656C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 2-amino-4h -pyraner
NO137900C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive, basisk substituerte teofyllin-derivater
NO136410C (no) Analogifremgangsm}te til fremstilling av antidiabetisk virksomme 3-metyl-pyrazol-5-karboksamider.